Alexza Pharmaceuticals, Inc.
Alexza initiates AZ-003 phase I clinical trial for anti-pain drug
Published in Pharma Law Weekly, May 23rd, 2006
AZ-003 is an inhalation product candidate being developed for the treatment of patients with acute pain episodes, including patients with breakthrough pain and postoperative patients.
The phase I clinical trial in approximately 50 healthy volunteers will be conducted at a single clinical center in two stages. Stage 1 is an open-label, cross-over comparison of a single dose of AZ-003 and an equivalent dose of intravenous (IV) fentanyl. Stage 2 is a randomized, doubleblind, placebo-controlled dose escalation trail of AZ-003,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-05-23)
More Articles from Pharma Law Weekly
- Business Update
BioScrip named national vendor for Medicare Part B - Business Update
Claimsnet announces contract with Medicare healthcare plan - Healthcare Costs
Weill Cornell awarded major federal contract and grant for public health research - Healthcare Coverage
Lack of health insurance associated with decreased use of health care services - Medicare
Medicare Part D Drug Plan enrollment experience provides valuable lessons for seniors - Medicare
Medicare provides payment increase, policy changes for inpatient psychiatric facilities - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
